{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:34:34Z","timestamp":1794065674131,"version":"4.8.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R41AG057274"],"award-info":[{"award-number":["1R41AG057274"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R21AG051820"],"award-info":[{"award-number":["1R21AG051820"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R41AG057274"],"award-info":[{"award-number":["1R41AG057274"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R21AG051820"],"award-info":[{"award-number":["1R21AG051820"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R21AG051820"],"award-info":[{"award-number":["1R21AG051820"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R41AG057274"],"award-info":[{"award-number":["1R41AG057274"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R41AG057274"],"award-info":[{"award-number":["1R41AG057274"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The neurodegenerative Alzheimer\u2019s disease (AD) affects more than 30 million people worldwide. There is thus far no cure or prevention for AD. Aggregation of hyperphosphorylated tau in the brain correlates with the cognitive decline of patients of AD and other neurodegenerative tauopathies. Intracerebral injection of tau aggregates isolated from tauopathy brains causes similar pathology in the recipient mice, demonstrating the pathogenic role of abnormally phosphorylated tau. Compounds controlling the aggregation of hyperphosphorylated tau therefore are probable modulators for the disease. Here we report the use of recombinant hyperphosphorylated tau (p-tau) to identify potential tauopathy therapeutics and risk factors. Hyperphosphorylation renders tau prone to aggregate and to impair cell viability. Taking advantage of these two characters of p-tau, we performed a screen of a 1280-compound library, and tested a selective group of prescription drugs in p-tau aggregation and cytotoxicity assays. R-(\u2212)-apomorphine and raloxifene were found to be p-tau aggregation inhibitors that protected p-tau-treated cells. In contrast, a subset of benzodiazepines exacerbated p-tau cytotoxicity apparently via enhancing p-tau aggregation. R-(\u2212)apomorphine and raloxifene have been shown to improve cognition in animals or in humans, whereas benzodiazepines were linked to increased risks of dementia. Our results demonstrate the feasibility and potential of using hyperphosphorylated tau-based assays for AD drug discovery and risk factor identification.<\/jats:p>","DOI":"10.1038\/s41598-020-73680-2","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T06:04:06Z","timestamp":1601964246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions"],"prefix":"10.1038","volume":"10","author":[{"given":"Mengyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dexheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Hovde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiexiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Bochar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"73680_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 297, 353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994 (2002).","journal-title":"Science"},{"key":"73680_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta, D., Jackson, R., Paul, G., Shi, J. & Sabbagh, M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015. Expert. Opin. Investig. Drugs 26, 735\u2013739. https:\/\/doi.org\/10.1080\/13543784.2017.1323868 (2017).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"73680_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Del Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389\u2013404. https:\/\/doi.org\/10.1007\/s00401-006-0127-z (2006).","journal-title":"Acta Neuropathol."},{"key":"73680_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71, 362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"73680_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5\u201321. https:\/\/doi.org\/10.1038\/nrn.2015.1 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"73680_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathmechdis-012418-012936","volume":"14","author":"J Gotz","year":"2019","unstructured":"Gotz, J., Halliday, G. & Nisbet, R. M. Molecular pathogenesis of the tauopathies. Ann. Rev. Pathol. 14, 239\u2013261. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012936 (2019).","journal-title":"Ann. Rev. Pathol."},{"key":"73680_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006296","author":"RE Tanzi","year":"2012","unstructured":"Tanzi, R. E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a006296 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"73680_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou, Y. et al. Ageing as a risk factor for neurodegenerative disease. Nature reviews. Neurology 15, 565\u2013581. https:\/\/doi.org\/10.1038\/s41582-019-0244-7 (2019).","journal-title":"Nature reviews. Neurology"},{"key":"73680_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41593-020-0599-5","volume":"23","author":"R Sims","year":"2020","unstructured":"Sims, R., Hill, M. & Williams, J. The multiplex model of the genetics of Alzheimer\u2019s disease. Nat. Neurosci. 23, 311\u2013322. https:\/\/doi.org\/10.1038\/s41593-020-0599-5 (2020).","journal-title":"Nat. Neurosci."},{"key":"73680_CR10","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1007\/s12035-018-1388-y","volume":"56","author":"GM Ashraf","year":"2019","unstructured":"Ashraf, G. M. et al. The possibility of an infectious etiology of Alzheimer disease. Mol. Neurobiol. 56, 4479\u20134491. https:\/\/doi.org\/10.1007\/s12035-018-1388-y (2019).","journal-title":"Mol. Neurobiol."},{"key":"73680_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbadis.2016.04.017","volume":"1863","author":"S Pugazhenthi","year":"2017","unstructured":"Pugazhenthi, S., Qin, L. & Reddy, P. H. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer\u2019s disease. Biochim. Biophysica Acta Mol. Basis Dis. 1863, 1037\u20131045. https:\/\/doi.org\/10.1016\/j.bbadis.2016.04.017 (2017).","journal-title":"Biochim. Biophysica Acta Mol. Basis Dis."},{"key":"73680_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1567205012666150204121719","volume":"12","author":"M Yegambaram","year":"2015","unstructured":"Yegambaram, M., Manivannan, B., Beach, T. G. & Halden, R. U. Role of environmental contaminants in the etiology of Alzheimer\u2019s disease: A review. Curr. Alzheimer Res. 12, 116\u2013146 (2015).","journal-title":"Curr. Alzheimer Res."},{"key":"73680_CR13","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2018.6346","author":"A Hicks","year":"2019","unstructured":"Hicks, A., James, A., Spitz, G. & Ponsford, J. Traumatic brain injury as a risk factor for dementia and Alzheimer\u2019s disease: Critical review of study methodologies. J. Neurotrauma https:\/\/doi.org\/10.1089\/neu.2018.6346 (2019).","journal-title":"J. Neurotrauma"},{"key":"73680_CR14","doi-asserted-by":"publisher","first-page":"g5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti de Gage","year":"2014","unstructured":"Billioti de Gage, S. et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: Case-control study. BMJ (Clinical research ed.) 349, g5205. https:\/\/doi.org\/10.1136\/bmj.g5205 (2014).","journal-title":"BMJ (Clinical research ed.)"},{"key":"73680_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray, S. L. et al. Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Intern. Med. 175, 401\u2013407. https:\/\/doi.org\/10.1001\/jamainternmed.2014.7663 (2015).","journal-title":"JAMA Intern. Med."},{"key":"73680_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0677","author":"CAC Coupland","year":"2019","unstructured":"Coupland, C. A. C. et al. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677 (2019).","journal-title":"JAMA Intern. Med."},{"key":"73680_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.taap.2017.09.014","volume":"334","author":"MH Chou","year":"2017","unstructured":"Chou, M. H., Wang, J. Y., Lin, C. L. & Chung, W. S. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case-control study. Toxicol. Appl. Pharmacol. 334, 217\u2013222. https:\/\/doi.org\/10.1016\/j.taap.2017.09.014 (2017).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"73680_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant, R., Goldstein, L. S. B. & Ossenkoppele, R. Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 21, 21\u201335. https:\/\/doi.org\/10.1038\/s41583-019-0240-3 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"73680_CR19","doi-asserted-by":"publisher","first-page":"8979","DOI":"10.1021\/jm301079z","volume":"55","author":"C Ballatore","year":"2012","unstructured":"Ballatore, C. et al. Microtubule stabilizing agents as potential treatment for Alzheimer\u2019s disease and related neurodegenerative tauopathies. J. Med. Chem. 55, 8979\u20138996. https:\/\/doi.org\/10.1021\/jm301079z (2012).","journal-title":"J. Med. Chem."},{"key":"73680_CR20","doi-asserted-by":"publisher","first-page":"873270","DOI":"10.1155\/2012\/873270","volume":"2012","author":"YD Ke","year":"2012","unstructured":"Ke, Y. D. et al. Lessons from tau-deficient mice. Int. J. Alzheimer\u2019s Dis. 2012, 873270. https:\/\/doi.org\/10.1155\/2012\/873270 (2012).","journal-title":"Int. J. Alzheimer's Dis."},{"key":"73680_CR21","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"CX Gong","year":"2008","unstructured":"Gong, C. X. & Iqbal, K. Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321\u20132328 (2008).","journal-title":"Curr. Med. Chem."},{"key":"73680_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fneur.2013.00083","volume":"4","author":"W Noble","year":"2013","unstructured":"Noble, W., Hanger, D. P., Miller, C. C. & Lovestone, S. The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol. 4, 83 (2013).","journal-title":"Front. Neurol."},{"key":"73680_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","volume":"15","author":"DP Hanger","year":"2009","unstructured":"Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112\u2013119. https:\/\/doi.org\/10.1016\/j.molmed.2009.01.003 (2009).","journal-title":"Trends Mol. Med."},{"key":"73680_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1062382","volume":"293","author":"CW Wittmann","year":"2001","unstructured":"Wittmann, C. W. et al. Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science 293, 711\u2013714. https:\/\/doi.org\/10.1126\/science.1062382 (2001).","journal-title":"Science"},{"key":"73680_CR25","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1073\/pnas.1301175110","volume":"110","author":"F Clavaguera","year":"2013","unstructured":"Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. 110, 9535\u20139540. https:\/\/doi.org\/10.1073\/pnas.1301175110 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"73680_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He, Z. et al. Amyloid-beta plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29\u201338. https:\/\/doi.org\/10.1038\/nm.4443 (2018).","journal-title":"Nat. Med."},{"key":"73680_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2014.08.032","volume":"73","author":"E Peeraer","year":"2015","unstructured":"Peeraer, E. et al. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis. 73, 83\u201395. https:\/\/doi.org\/10.1016\/j.nbd.2014.08.032 (2015).","journal-title":"Neurobiol. Dis."},{"key":"73680_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ncb1901","volume":"11","author":"F Clavaguera","year":"2009","unstructured":"Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell. Biol. 11, 909\u2013913. https:\/\/doi.org\/10.1038\/ncb1901 (2009).","journal-title":"Nat. Cell. Biol."},{"key":"73680_CR29","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.1074\/jbc.M808759200","volume":"284","author":"B Frost","year":"2009","unstructured":"Frost, B., Jacks, R. L. & Diamond, M. I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845\u201312852. https:\/\/doi.org\/10.1074\/jbc.M808759200 (2009).","journal-title":"J. Biol. Chem."},{"key":"73680_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-6-39","volume":"6","author":"CA Lasagna-Reeves","year":"2011","unstructured":"Lasagna-Reeves, C. A. et al. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6, 39. https:\/\/doi.org\/10.1186\/1750-1326-6-39 (2011).","journal-title":"Mol. Neurodegener."},{"key":"73680_CR31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085\u20131092. https:\/\/doi.org\/10.1038\/nn.4328 (2016).","journal-title":"Nat. Neurosci."},{"key":"73680_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201592748","author":"S Wegmann","year":"2015","unstructured":"Wegmann, S. et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. Embo J. https:\/\/doi.org\/10.15252\/embj.201592748 (2015).","journal-title":"Embo J."},{"key":"73680_CR33","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.celrep.2018.04.056","volume":"23","author":"T Katsinelos","year":"2018","unstructured":"Katsinelos, T. et al. Unconventional secretion mediates the trans-cellular spreading of tau. Cell Rep. 23, 2039\u20132055. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.056 (2018).","journal-title":"Cell Rep."},{"key":"73680_CR34","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.celrep.2018.10.078","volume":"25","author":"M Merezhko","year":"2018","unstructured":"Merezhko, M. et al. Secretion of tau via an unconventional non-vesicular mechanism. Cell Rep. 25, 2027-2035.e2024. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.078 (2018).","journal-title":"Cell Rep."},{"key":"73680_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nm.3457","volume":"20","author":"JL Guo","year":"2014","unstructured":"Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130\u2013138. https:\/\/doi.org\/10.1038\/nm.3457 (2014).","journal-title":"Nat. Med."},{"key":"73680_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","volume":"40","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Eisenberg, D. S. & Crowther, R. A. Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci. 40, 189\u2013210. https:\/\/doi.org\/10.1146\/annurev-neuro-072116-031153 (2017).","journal-title":"Annu. Rev. Neurosci."},{"key":"73680_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch, J. N. et al. LRP1 is a master regulator of tau uptake and spread. Nature 580, 381\u2013385. https:\/\/doi.org\/10.1038\/s41586-020-2156-5 (2020).","journal-title":"Nature"},{"key":"73680_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00401-015-1415-2","volume":"129","author":"M Takahashi","year":"2015","unstructured":"Takahashi, M. et al. Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. Acta Neuropathol. 129, 895\u2013907. https:\/\/doi.org\/10.1007\/s00401-015-1415-2 (2015).","journal-title":"Acta Neuropathol."},{"key":"73680_CR39","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41467-017-01575-4","volume":"8","author":"N Ait-Bouziad","year":"2017","unstructured":"Ait-Bouziad, N. et al. Discovery and characterization of stable and toxic tau\/phospholipid oligomeric complexes. Nat. Commun. 8, 1678. https:\/\/doi.org\/10.1038\/s41467-017-01575-4 (2017).","journal-title":"Nat. Commun."},{"key":"73680_CR40","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1523\/jneurosci.0587-07.2007","volume":"27","author":"Z Berger","year":"2007","unstructured":"Berger, Z. et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650\u20133662. https:\/\/doi.org\/10.1523\/jneurosci.0587-07.2007 (2007).","journal-title":"J. Neurosci."},{"key":"73680_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/2051-5960-2-56","volume":"2","author":"CA Lasagna-Reeves","year":"2014","unstructured":"Lasagna-Reeves, C. A. et al. The formation of tau pore-like structures is prevalent and cell specific: Possible implications for the disease phenotypes. Acta Neuropathol. Commun. 2, 56. https:\/\/doi.org\/10.1186\/2051-5960-2-56 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"73680_CR42","doi-asserted-by":"publisher","first-page":"43223","DOI":"10.1074\/jbc.M112.396176","volume":"287","author":"K Flach","year":"2012","unstructured":"Flach, K. et al. Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 287, 43223\u201343233. https:\/\/doi.org\/10.1074\/jbc.M112.396176 (2012).","journal-title":"J. Biol. Chem."},{"key":"73680_CR43","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1021\/bi1016233","volume":"49","author":"CA Lasagna-Reeves","year":"2010","unstructured":"Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R. & Kayed, R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039\u201310041. https:\/\/doi.org\/10.1021\/bi1016233 (2010).","journal-title":"Biochemistry"},{"key":"73680_CR44","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1021\/cn500143n","volume":"5","author":"JE Gerson","year":"2014","unstructured":"Gerson, J. E., Castillo-Carranza, D. L. & Kayed, R. Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species. ACS Chem. Neurosci. 5, 752\u2013769. https:\/\/doi.org\/10.1021\/cn500143n (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"73680_CR45","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1074\/jbc.M410984200","volume":"280","author":"M Pickhardt","year":"2005","unstructured":"Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer\u2019s paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628\u20133635. https:\/\/doi.org\/10.1074\/jbc.M410984200 (2005).","journal-title":"J. Biol. Chem."},{"key":"73680_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2007.03.056","volume":"358","author":"A Crowe","year":"2007","unstructured":"Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q. & Lee, V. M. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2007.03.056 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"73680_CR47","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1074\/jbc.M408714200","volume":"280","author":"S Taniguchi","year":"2005","unstructured":"Taniguchi, S. et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614\u20137623. https:\/\/doi.org\/10.1074\/jbc.M408714200 (2005).","journal-title":"J. Biol. Chem."},{"key":"73680_CR48","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/s0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (London, England) 388, 2873\u20132884. https:\/\/doi.org\/10.1016\/s0140-6736(16)31275-2 (2016).","journal-title":"Lancet (London, England)"},{"key":"73680_CR49","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","volume":"288","author":"A Crowe","year":"2013","unstructured":"Crowe, A. et al. Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J. Biol. Chem. 288, 11024\u201311037. https:\/\/doi.org\/10.1074\/jbc.M112.436006 (2013).","journal-title":"J. Biol. Chem."},{"key":"73680_CR50","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1073\/pnas.92.18.8463","volume":"92","author":"O Schweers","year":"1995","unstructured":"Schweers, O., Mandelkow, E. M., Biernat, J. & Mandelkow, E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. USA 92, 8463\u20138467 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73680_CR51","doi-asserted-by":"publisher","first-page":"10216","DOI":"10.1038\/ncomms10216","volume":"6","author":"Y Soeda","year":"2015","unstructured":"Soeda, Y. et al. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat. Commun. 6, 10216. https:\/\/doi.org\/10.1038\/ncomms10216 (2015).","journal-title":"Nat. Commun."},{"key":"73680_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/open.201800222","volume":"8","author":"C Areche","year":"2019","unstructured":"Areche, C. et al. Anthraquinone derivative reduces tau oligomer progression by inhibiting cysteine-cysteine interaction. ChemistryOpen 8, 554\u2013559. https:\/\/doi.org\/10.1002\/open.201800222 (2019).","journal-title":"ChemistryOpen"},{"key":"73680_CR53","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1074\/jbc.M114.589309","volume":"290","author":"B Falcon","year":"2015","unstructured":"Falcon, B. et al. Conformation determines the seeding potencies of native and recombinant tau aggregates. J. Biol. Chem. 290, 1049\u20131065. https:\/\/doi.org\/10.1074\/jbc.M114.589309 (2015).","journal-title":"J. Biol. Chem."},{"key":"73680_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1326-2-12","volume":"2","author":"CA Rankin","year":"2007","unstructured":"Rankin, C. A., Sun, Q. & Gamblin, T. C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol. Neurodegener. 2, 12. https:\/\/doi.org\/10.1186\/1750-1326-2-12 (2007).","journal-title":"Mol. Neurodegener."},{"key":"73680_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1471-4159.2006.04052.x","volume":"99","author":"H Yoshida","year":"2006","unstructured":"Yoshida, H. & Goedert, M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4\/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J. Neurochem. 99, 154\u2013164. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04052.x (2006).","journal-title":"J. Neurochem."},{"key":"73680_CR56","doi-asserted-by":"publisher","first-page":"34389","DOI":"10.1074\/jbc.M114.611368","volume":"289","author":"K Tepper","year":"2014","unstructured":"Tepper, K. et al. Oligomer formation of tau protein hyperphosphorylated in cells. J. Biol. Chem. 289, 34389\u201334407. https:\/\/doi.org\/10.1074\/jbc.M114.611368 (2014).","journal-title":"J. Biol. Chem."},{"key":"73680_CR57","doi-asserted-by":"publisher","first-page":"6923","DOI":"10.1073\/pnas.121119298","volume":"98","author":"A Alonso","year":"2001","unstructured":"Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments\/straight filaments. Proc. Natl. Acad. Sci. USA 98, 6923\u20136928. https:\/\/doi.org\/10.1073\/pnas.121119298 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73680_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190. https:\/\/doi.org\/10.1038\/nature23002 (2017).","journal-title":"Nature"},{"key":"73680_CR59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1074\/mcp.O114.044412","volume":"14","author":"D Sui","year":"2015","unstructured":"Sui, D. et al. Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5\/p25 kinase complex. Mol. Cell Proteomics 14, 251\u2013262. https:\/\/doi.org\/10.1074\/mcp.O114.044412 (2015).","journal-title":"Mol. Cell Proteomics"},{"key":"73680_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-02034-w","author":"M Liu","year":"2020","unstructured":"Liu, M. et al. Hyperphosphorylation renders tau prone to aggregate and to cause cell death. Mol. Neurobiol. https:\/\/doi.org\/10.1007\/s12035-020-02034-w (2020).","journal-title":"Mol. Neurobiol."},{"key":"73680_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tins.2008.11.007","volume":"32","author":"TL Spires-Jones","year":"2009","unstructured":"Spires-Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P. B. & Hyman, B. T. Tau pathophysiology in neurodegeneration: A tangled issue. Trends Neurosci. 32, 150\u2013159. https:\/\/doi.org\/10.1016\/j.tins.2008.11.007 (2009).","journal-title":"Trends Neurosci."},{"key":"73680_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67\u201373 (1999).","journal-title":"J. Biomol. Screen."},{"key":"73680_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-3673-1_1","volume":"1439","author":"DJ Powell","year":"2016","unstructured":"Powell, D. J., Hertzberg, R. P. & Macarromicronn, R. Design and implementation of high-throughput screening assays. Methods Mol. Biol. 1439, 1\u201332. https:\/\/doi.org\/10.1007\/978-1-4939-3673-1_1 (2016).","journal-title":"Methods Mol. Biol."},{"key":"73680_CR64","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.62.6_suppl_4.S8","volume":"62","author":"PA LeWitt","year":"2004","unstructured":"LeWitt, P. A. Subcutaneously administered apomorphine: Pharmacokinetics and metabolism. Neurology 62, S8-11 (2004).","journal-title":"Neurology"},{"key":"73680_CR65","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1677\/jme-10-0122","volume":"46","author":"MA Arevalo","year":"2011","unstructured":"Arevalo, M. A., Santos-Galindo, M., Lagunas, N., Azcoitia, I. & Garcia-Segura, L. M. Selective estrogen receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 46, R1\u2013R9. https:\/\/doi.org\/10.1677\/jme-10-0122 (2011).","journal-title":"J. Mol. Endocrinol."},{"key":"73680_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/nano8020087","author":"L Montenegro","year":"2018","unstructured":"Montenegro, L., Turnaturi, R., Parenti, C. & Pasquinucci, L. Idebenone: Novel strategies to improve its systemic and local efficacy. Nanomaterials (Basel, Switzerland) https:\/\/doi.org\/10.3390\/nano8020087 (2018).","journal-title":"Nanomaterials (Basel, Switzerland)"},{"key":"73680_CR67","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3233\/jad-160344","volume":"58","author":"N Nakamura","year":"2017","unstructured":"Nakamura, N. et al. Apomorphine therapy for neuronal insulin resistance in a mouse model of Alzheimer\u2019s disease. J. Alzheimers Dis. 58, 1151\u20131161. https:\/\/doi.org\/10.3233\/jad-160344 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"73680_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.162.4.683","volume":"162","author":"K Yaffe","year":"2005","unstructured":"Yaffe, K. et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry 162, 683\u2013690. https:\/\/doi.org\/10.1176\/appi.ajp.162.4.683 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"73680_CR69","doi-asserted-by":"publisher","first-page":"e0127836","DOI":"10.1371\/journal.pone.0127836","volume":"10","author":"G Zhong","year":"2015","unstructured":"Zhong, G., Wang, Y., Zhang, Y. & Zhao, Y. Association between benzodiazepine use and dementia: A meta-analysis. PLoS ONE 10, e0127836. https:\/\/doi.org\/10.1371\/journal.pone.0127836 (2015).","journal-title":"PLoS ONE"},{"key":"73680_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","volume":"18","author":"G Airagnes","year":"2016","unstructured":"Airagnes, G., Pelissolo, A., Lavallee, M., Flament, M. & Limosin, F. Benzodiazepine misuse in the elderly: Risk factors, consequences, and management. Curr. Psychiatry Rep. 18, 89. https:\/\/doi.org\/10.1007\/s11920-016-0727-9 (2016).","journal-title":"Curr. Psychiatry Rep."},{"key":"73680_CR71","first-page":"214","volume":"13","author":"CE Griffin 3rd","year":"2013","unstructured":"Griffin, C. E. 3rd., Kaye, A. M., Bueno, F. R. & Kaye, A. D. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 13, 214\u2013223 (2013).","journal-title":"Ochsner J."},{"key":"73680_CR72","doi-asserted-by":"publisher","first-page":"i4474","DOI":"10.1136\/bmj.i4474","volume":"354","author":"J Wise","year":"2016","unstructured":"Wise, J. No \u201cbreakthrough\u201d in Alzheimer\u2019s disease. BMJ (Clinical research ed.) 354, i4474. https:\/\/doi.org\/10.1136\/bmj.i4474 (2016).","journal-title":"BMJ (Clinical research ed.)"},{"key":"73680_CR73","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 21, 1341\u20131349. https:\/\/doi.org\/10.1038\/s41593-018-0238-6 (2018).","journal-title":"Nat. Neurosci."},{"key":"73680_CR74","first-page":"553","volume":"3","author":"AK Gupta","year":"2004","unstructured":"Gupta, A. K. & Chow, M. Prednicarbate (dermatop): A review. J. Drugs Dermatol.JDD 3, 553\u2013556 (2004).","journal-title":"J. Drugs Dermatol.JDD"},{"key":"73680_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020045","author":"HS Nguyen","year":"2018","unstructured":"Nguyen, H. S., Awad, A. J., Shabani, S. & Doan, N. Molecular targeting of acid ceramidase in glioblastoma: A review of its role, potential treatment, and challenges. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics10020045 (2018).","journal-title":"Pharmaceutics"},{"key":"73680_CR76","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fneur.2019.00713","volume":"10","author":"A Fesharaki-Zadeh","year":"2019","unstructured":"Fesharaki-Zadeh, A. Chronic traumatic encephalopathy: A brief overview. Front. Neurol. 10, 713. https:\/\/doi.org\/10.3389\/fneur.2019.00713 (2019).","journal-title":"Front. Neurol."},{"key":"73680_CR77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pnpbp.2013.03.004","volume":"47","author":"RA Whittington","year":"2013","unstructured":"Whittington, R. A., Bretteville, A., Dickler, M. F. & Planel, E. Anesthesia and tau pathology. Prog. Neuropsychopharmacol. Biol. Psychiatry 47, 147\u2013155. https:\/\/doi.org\/10.1016\/j.pnpbp.2013.03.004 (2013).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"73680_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neulet.2015.10.036","volume":"609","author":"P Arun","year":"2015","unstructured":"Arun, P. et al. Acute decrease in alkaline phosphatase after brain injury: A potential mechanism for tauopathy. Neurosci. Lett. 609, 152\u2013158. https:\/\/doi.org\/10.1016\/j.neulet.2015.10.036 (2015).","journal-title":"Neurosci. Lett."},{"key":"73680_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2018.10.027","volume":"75","author":"RA Whittington","year":"2019","unstructured":"Whittington, R. A. et al. Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain. Neurobiol. Aging 75, 11\u201324. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.10.027 (2019).","journal-title":"Neurobiol. Aging"},{"key":"73680_CR80","doi-asserted-by":"publisher","first-page":"3234013","DOI":"10.1155\/2020\/3234013","volume":"2020","author":"JJ Lee","year":"2020","unstructured":"Lee, J. J. et al. Relationship between surgery under general anesthesia and the development of dementia: A systematic review and meta-analysis. Biomed. Res. Int. 2020, 3234013. https:\/\/doi.org\/10.1155\/2020\/3234013 (2020).","journal-title":"Biomed. Res. Int."},{"key":"73680_CR81","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1517\/14656566.2013.782002","volume":"14","author":"P D'Amelio","year":"2013","unstructured":"D\u2019Amelio, P. & Isaia, G. C. The use of raloxifene in osteoporosis treatment. Expert Opin. Pharmacother. 14, 949\u2013956. https:\/\/doi.org\/10.1517\/14656566.2013.782002 (2013).","journal-title":"Expert Opin. Pharmacother."},{"key":"73680_CR82","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/wnl.0000000000002171","volume":"85","author":"VW Henderson","year":"2015","unstructured":"Henderson, V. W. et al. Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial. Neurology 85, 1937\u20131944. https:\/\/doi.org\/10.1212\/wnl.0000000000002171 (2015).","journal-title":"Neurology"},{"key":"73680_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.300.1.2","volume":"300","author":"H Mohler","year":"2002","unstructured":"Mohler, H., Fritschy, J. M. & Rudolph, U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Therap. 300, 2\u20138 (2002).","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"73680_CR84","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2967\/jnumed.110.086629","volume":"52","author":"AM Scarf","year":"2011","unstructured":"Scarf, A. M. & Kassiou, M. The translocator protein. J. Nucl. Med. 52, 677\u2013680. https:\/\/doi.org\/10.2967\/jnumed.110.086629 (2011).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73680-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:18:57Z","timestamp":1670339937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73680-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73680"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73680-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16551"}}